This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Charting New Pathways to Achieve Optimal Control of Moderate to Severe Asthma

Charting New Pathways to Achieve Optimal Control of Moderate to Severe Asthma



Time to Complete

1.25 hours


June 29, 2018


June 29, 2019
Add to Queue

Maximum Credits

1.25 / AMA PRA Category 1 Credit(s)TM

Accredited Providers

Provided by Haymarket Medical Education

Commercial Supporter

Supported by educational grants from AstraZeneca and Novartis Pharmaceuticals Corporation

Program Description

Welcome to the inaugural myCME TOWN WALL™. This unique platform allows you to hear from a wide variety of experts through an engaging visual display. The focus of this program is severe asthma.

Given the chronic and inflammatory nature of asthma, many patients with asthma have persistent daily symptoms and exacerbations despite compliance with high doses of inhaled steroids, long-acting beta-agonists, and other supplemental therapies. Factors that play a role in poor asthma control include clinician lack of awareness of current treatment guidelines and a failure to use validated tools to assess severity; different perceptions or definitions of control between the patient and the clinician; lack of adherence to therapy; poor inhaler technique and inadequate dosing; and patient misconceptions regarding specific agents. In light of these challenges, respiratory specialists and primary care providers should become familiar with inflammatory mediators such as immunoglobulin E (IgE), interleukin-5 (IL-5), and IL-13, along with recently approved asthma therapies that address the pathophysiologic abnormalities associated with moderate to severe, often hard-to-treat asthma. For such patients, there is a need to integrate into practice contemporary approaches to asthma management that are aligned with published guidelines and accepted standards of care. Healthcare providers also should work in concert with patients in the selection of therapies and of the most appropriate delivery device to foster improved adherence and overall outcomes.

Intended Audience

The proposed activity is designed for allergists/immunologists, pulmonologists, and primary care clinicians (family medicine and internal medicine [IM] physicians, nurse practitioners [NPs], and physician assistants [PAs]).

Educational Objectives

After completing the activity, the participant should be better able to:

  • Evaluate the role of inflammatory mediators and other abnormalities in the pathogenesis of asthma
  • Apply evidence-based guidelines to individualized treatment plans for patients with asthma
  • Develop collaborative treatment strategies and a stronger provider-patient partnership to ensure optimal control of moderate to severe asthma
  • Analyze the safety and efficacy of new and emerging agents for the management of poorly controlled asthma

Conflict Of Interest Disclosure Policies

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.


Peter Salgo, MD
Professor of Medicine and Anesthesiology
Columbia University College of Physicians and Surgeons
Associate Director Surgical Intensive Care
Columbia University Medical Center
New York, NY

Dr. Salgo has no relevant financial relationships to disclose.


Michael S. Blaiss, MD, FACAAI
Clinical Professor of Pediatrics
Medical College of Georgia at Augusta University
Augusta, GA

Dr. Blaiss is a consultant for ALK, Bayer, Boston Scientific, Hycor BioMedical, Pfizer Inc., PMD Healthcare, Regeneron, Sanofi, and Stallergenes Greer.

Nicola Hanania, MD, MS
Associate Professor of Medicine
Director, Airways Clinical Research Center
Baylor College of Medicine
Houston, TX

Dr. Hanania is a consultant for AstraZeneca, Boehringer lngelheim, GSK, Novartis, and Sanofi/Regeneron and is an investigator for AstraZeneca, Boehringer lngelheim, Genentech, and GSK.

Eli O. Meltzer, MD
Department of Pediatrics
Division of Allergy and Immunology
University of California
Allergy & Asthma Medical Group and Research Center
San Diego, CA

Dr. Meltzer is a consultant for ALK Inc., Allergan, AstraZeneca, GSK, Glenmark, and Regeneron/Sanofi; is on the speakers’ bureaus for ALK, Mylan, and Stallergenes Greer; and is an investigator for HealthLogiX.

Accredited Provider Disclosure

Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.


Ingrid Cantrell, PA
Allergy & Asthma Care
Germantown, TN

Ms. Cantrell has no relevant financial relationships to disclose.

Dharani Kumari Narendra, MD
Assistant Professor of Medicine
Pulmonary, Critical Care, and Sleep Section
Baylor College of Medicine
Houston, TX

Dr. Narendra has no relevant financial relationships to disclose.

Amit Parulekar, MD, MS
Assistant Professor of Medicine
Section of Pulmonary, Critical Care, and Sleep Medicine
Baylor College of Medicine
Houston, TX

Dr. Parulekar has no relevant financial relationships to disclose.

Michael J. Welch, MD, FAAP, FAAAAI
Co-director, Allergy & Asthma Medical Group and Research Center
Clinical Professor
University of California at San Diego School of Medicine
San Diego, CA

Dr. Welch has no relevant financial relationships to disclose.

Ari Zelig, MD
Allergy Associates of Sarasota and Venice
Sarasota, FL

Dr. Zelig has no relevant financial relationships to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Haymarket Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM .   Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education, AstraZeneca, or Novartis Pharmaceuticals Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact Haymarket Medical Education.

If you have any other questions relating to your certificate or other issues with the activity, please contact


To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue